Phase 4 Atrial Fibrillation Trial, Recruiting (NCT04642430)

Phase 4 Atrial Fibrillation Trial, Recruiting NCT04642430 Sponsor: Ottawa Hospital Research Institute Condition: Atrial Fibrillation

Printed from Voxsanity (voxsanity.com.au) — NCT04642430 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Atrial Fibrillation

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years of age or older
You have been recently diagnosed with atrial fibrillation (an irregular heartbeat), confirmed by a heart tracing test (ECG), and your doctor has determined you need to start blood thinning medication

Who may not be able to join:

Your kidneys are not working well enough (specifically, your kidney function score is very low — confirm with trial site)
Your doctor has decided that certain blood thinning medications (apixaban or rivaroxaban) are not safe for you for any reason
You are currently experiencing active bleeding
You have a mechanical (artificial) heart valve
You are already taking blood thinners for another reason, such as a blood clot in your veins
You are currently taking two different blood-thinning/anti-clotting medications at the same time (confirm with trial site)
You have a liver condition that affects your blood's ability to clot
You are taking certain other medications that could interfere with these blood thinners (confirm with trial site)
You are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Lana Castellucci, MD, FRCPC, Ottawa Hospital Research Institute

Phone: 613-737-8899

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04642430

Sponsor: Ottawa Hospital Research Institute

Phase: Phase 4

Status: Recruiting

Condition: Atrial Fibrillation

Trial contact: 613-737-8899

More information: https://clinicaltrials.gov/study/NCT04642430

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years of age or older
You have been recently diagnosed with atrial fibrillation (an irregular heartbeat), confirmed by a heart tracing test (ECG), and your doctor has determined you need to start blood thinning medication

Who may not be able to join:

Your kidneys are not working well enough (specifically, your kidney function score is very low — confirm with trial site)
Your doctor has decided that certain blood thinning medications (apixaban or rivaroxaban) are not safe for you for any reason
You are currently experiencing active bleeding
You have a mechanical (artificial) heart valve
You are already taking blood thinners for another reason, such as a blood clot in your veins
You are currently taking two different blood-thinning/anti-clotting medications at the same time (confirm with trial site)
You have a liver condition that affects your blood's ability to clot
You are taking certain other medications that could interfere with these blood thinners (confirm with trial site)
You are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Ottawa Hospital Research Institute

Registry

ClinicalTrials.gov

Start date

6 July 2021

Est. completion

31 December 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

The rate of adjudicated clinically relevant bleeding (CRB) events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov